MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
10.46
+0.08
+0.77%
Pre Market: 10.25 -0.21 -2.01% 08:06 05/14 EDT
OPEN
10.28
PREV CLOSE
10.38
HIGH
10.62
LOW
9.87
VOLUME
682
TURNOVER
0
52 WEEK HIGH
24.28
52 WEEK LOW
1.060
MARKET CAP
3.25B
P/E (TTM)
-11.2136
1D
5D
1M
3M
1Y
5Y
1D
The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift
Simply Wall St · 15h ago
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Barchart · 1d ago
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 1d ago
Erasca Price Target Cut to $26.00/Share From $28.00 by Mizuho
Dow Jones · 1d ago
Erasca Is Maintained at Outperform by Mizuho
Dow Jones · 1d ago
Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26
Benzinga · 1d ago
Erasca price target lowered to $26 from $28 at Mizuho
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS), Canopy Growth (CGC) and Alkermes (ALKS)
TipRanks · 2d ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.